Discontinued — last reported Q3 '22
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $23.00M | $0.00 | -$239.00M | $250.00M | $236.00M | $302.00M | $0.00 | $0.00 | $0.00 | $289.00M | $0.00 | $0.00 |
| QoQ Change | — | — | — | — | — | — | -100.0% | — | +204.6% | -5.6% | +28.0% | -100.0% | — | — | — | -100.0% | — |
| YoY Change | — | — | — | — | — | — | — | — | — | +926.1% | — | +100.0% | -100.0% | -100.0% | -4.3% | — | — |
We use cookies for analytics. See our Privacy and Cookie Policy.